Triple-Threat attack on prostate cancer shows promise
NCT ID NCT02023463
Summary
This early-stage trial is testing whether combining three different treatments is safe for men with aggressive prostate cancer. The approach uses a hormone-blocking drug (enzalutamide), radiation therapy, and standard hormone injections to attack the cancer from multiple angles. Researchers are primarily watching for side effects while also tracking how well the combination controls cancer markers like PSA levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.